BACKGROUND: Nonresponsive celiac disease (CD) is defined by persistent or recurrent symptoms, common after treatment with a gluten-free diet (GFD). OBJECTIVE: To evaluate the utility of capsule endoscopy (CE) in nonresponsive CD. DESIGN: Case-control study. SETTING: Tertiary-care center. PATIENTS: Forty-two consecutive patients with nonresponsive CD and 84 age- and sex-matched CD-free controls who underwent CE were included. In addition, capsules taken after treatment with a GFD were retrospectively evaluated in 30 patients with uncomplicated CD. INTERVENTION: CE. MAIN OUTCOME MEASUREMENTS: Diagnostic accuracy of CE for the detection of mucosal abnormalities in nonresponsive CD. RESULTS: Macroscopic features of villous atrophy were detected in 13 of 42 patients (31%) with nonresponsive CD compared with none among 84 CD-free controls and 14 of 30 patients (47%) with uncomplicated CD. Among nonresponsive CD cases, the overall sensitivity and specificity of CE for the detection of any degree of villous atrophy as graded by histology were 56% and 85%, respectively. Single or multiple erosions/ulcerations of the gut were observed in 19% of nonresponsive CD patients, 18% of CD-free controls, and 31% of patients with uncomplicated CD (P = .35). The presence of erosions/ulcerations was associated with increased aspirin/nonsteroidal anti-inflammatory drug use in nonresponsive CD (P =.05). Two severe complications (ulcerative jejunitis and adenocarcinoma) were detected by CE in nonresponsive CD. LIMITATIONS: Single-center, retrospective study. CONCLUSIONS: Mucosal abnormalities were observed by CE in patients with both nonresponsive CD and uncomplicated CD. CE can detect severe complications in patients with nonresponsive CD.
BACKGROUND: Nonresponsive celiac disease (CD) is defined by persistent or recurrent symptoms, common after treatment with a gluten-free diet (GFD). OBJECTIVE: To evaluate the utility of capsule endoscopy (CE) in nonresponsive CD. DESIGN: Case-control study. SETTING: Tertiary-care center. PATIENTS: Forty-two consecutive patients with nonresponsive CD and 84 age- and sex-matched CD-free controls who underwent CE were included. In addition, capsules taken after treatment with a GFD were retrospectively evaluated in 30 patients with uncomplicated CD. INTERVENTION: CE. MAIN OUTCOME MEASUREMENTS: Diagnostic accuracy of CE for the detection of mucosal abnormalities in nonresponsive CD. RESULTS: Macroscopic features of villous atrophy were detected in 13 of 42 patients (31%) with nonresponsive CD compared with none among 84 CD-free controls and 14 of 30 patients (47%) with uncomplicated CD. Among nonresponsive CD cases, the overall sensitivity and specificity of CE for the detection of any degree of villous atrophy as graded by histology were 56% and 85%, respectively. Single or multiple erosions/ulcerations of the gut were observed in 19% of nonresponsive CD patients, 18% of CD-free controls, and 31% of patients with uncomplicated CD (P = .35). The presence of erosions/ulcerations was associated with increased aspirin/nonsteroidal anti-inflammatory drug use in nonresponsive CD (P =.05). Two severe complications (ulcerative jejunitis and adenocarcinoma) were detected by CE in nonresponsive CD. LIMITATIONS: Single-center, retrospective study. CONCLUSIONS:Mucosal abnormalities were observed by CE in patients with both nonresponsive CD and uncomplicated CD. CE can detect severe complications in patients with nonresponsive CD.
Authors: Kouroche Vahedi; Françoise Mascart; Jean Yves Mary; Jean Eric Laberenne; Yoram Bouhnik; Marie Christine Morin; Annick Ocmant; Christine Velly; Jean Frédéric Colombel; Claude Matuchansky Journal: Am J Gastroenterol Date: 2003-05 Impact factor: 10.864
Authors: Edward J Ciaccio; Christina A Tennyson; Govind Bhagat; Suzanne K Lewis; Peter H Green Journal: Dig Dis Sci Date: 2012-05-30 Impact factor: 3.199
Authors: Joseph A Murray; Stela McLachlan; Paul C Adams; John H Eckfeldt; Chad P Garner; Chris D Vulpe; Victor R Gordeuk; Tricia Brantner; Catherine Leiendecker-Foster; Anthony A Killeen; Ronald T Acton; Lisa F Barcellos; Debbie A Nickerson; Kenneth B Beckman; Gordon D McLaren; Christine E McLaren Journal: Clin Gastroenterol Hepatol Date: 2013-02-13 Impact factor: 11.382
Authors: Alberto Rubio-Tapia; Ivor D Hill; Ciarán P Kelly; Audrey H Calderwood; Joseph A Murray Journal: Am J Gastroenterol Date: 2013-04-23 Impact factor: 10.864
Authors: Maureen M Leonard; Jocelyn A Silvester; Daniel Leffler; Alessio Fasano; Ciarán P Kelly; Suzanne K Lewis; Jeffrey D Goldsmith; Elliot Greenblatt; William W Kwok; William J McAuliffe; Kevin Galinsky; Jenifer Siegelman; I-Ting Chow; John A Wagner; Anna Sapone; Glennda Smithson Journal: Gastroenterology Date: 2020-10-29 Impact factor: 22.682
Authors: Jonas F Ludvigsson; Julio C Bai; Federico Biagi; Timothy R Card; Carolina Ciacci; Paul J Ciclitira; Peter H R Green; Marios Hadjivassiliou; Anne Holdoway; David A van Heel; Katri Kaukinen; Daniel A Leffler; Jonathan N Leonard; Knut E A Lundin; Norma McGough; Mike Davidson; Joseph A Murray; Gillian L Swift; Marjorie M Walker; Fabiana Zingone; David S Sanders Journal: Gut Date: 2014-06-10 Impact factor: 23.059